Tela Bio Inc (TELA) - News Archive

Malvern, Pa. As part of its ongoing strategy to attract top talent and foster growth, TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company dedicated to advancing soft-tissue reconstruction soluti...

Revolutionizing Reconstructive Surgery: TELA Bio Launches Larger OviTex PRS Options, Outshining the Competition In the ever-evolving world of medical technology, innovation isn’t just a buzzword; it’s a necessity. TELA...

In a significant move to bolster its team, TELA Bio, Inc. (NASDAQ: TELA), a leading commercial-stage medical technology firm specializing in innovative soft-tissue reconstruction solutions, has disclosed the approval of...

In a strategic move to enhance its operational capacity, TELA Bio, Inc. (NASDAQ: TELA) announced on January 24, 2025, the approval of inducement grants covering 4,000 shares of its common stock to seven newly-hired empl...

TELA Bio: Strategic Inducement Grants and What They Mean for InvestorsIn a market where talent acquisition can dramatically shape the future trajectory of a company, TELA Bio, Inc. is taking significant steps to bolster...

Advancements in Soft-Tissue Reconstruction: TELA Bio s Strategic Innovations and Inducement Efforts MALVERN, Pa. Nov. 01, 2024 TELA Bio, Inc. (NASDAQ: TELA), a distinguished player in the medical technology sphere, cont...

MALVERN, Pa. TELA Bio, Inc. (“TELA”), a prominent player in the medical technology sector with a focus on innovative soft-tissue reconstruction, announced on October 24, 2024, the successful closing of its recently comp...

TELA Bio, Inc. Announces $40 Million Public Offering: What This Means for Shareholders and Future GrowthIn a strategic move that reflects its ongoing commitment to innovation and expansion in soft-tissue reconstruction,...

In a strategic move to bolster its team and potential market capabilities, TELA Bio, Inc. (NASDAQ: TELA) announced the approval of inducement grants of restricted stock units (RSUs) for nine newly-hired employees. This...

TELA Bio s Inducement Grants Signal Promising Growth ProspectsMALVERN, Pa., May 10, 2024 - TELA Bio, Inc. (NASDAQ: TELA), a renowned medical technology company specializing in innovative soft-tissue reconstruction solut...

TELA Bio, a leading innovator in the field of regenerative medicine, has recently announced the commercial launch of their groundbreaking product, Robotic-Compatible OviTex IHR. This cutting-edge solution aims to addres...

TELA Bio s decision to bring on board Dr. Langstein is a strategic move aimed at leveraging his expertise to improve clinical outcomes in the field of plastic and reconstructive surgery. With his extensive experience an...

TELA Bio, a pioneering medical device company, has recently introduced LIQUIFIX, the first-ever FDA-approved liquid adhesive specifically designed for internal use in hernia surgeries. This groundbreaking product marks...

TELA Bio Inc., a leading medical technology company, has recently announced an agreement to sell distribution rights for its innovative wound care product to MIMEDX. This promising development comes at a crucial time fo...

TELA Bio Approves Inducement Grants for New Employees Under Nasdaq Rule 5635(c)(4)TELA Bio, Inc. (NASDAQ: TELA), a medical technology company specializing in soft-tissue reconstruction solutions, has recently announced...

TELA Bio, Inc. (“TELA Bio”), a leading medical technology company committed to revolutionizing soft-tissue reconstruction solutions that prioritize the preservation and restoration of patients own anatomy, disclosed tod...

IntroductionTELA Bio, a leading medical technology company specializing in soft-tissue reconstruction solutions, has recently announced its approval of inducement grants in the form of restricted stock units (RSUs). The...

TELA Bio s Inducement Grants:TELA Bio has authorized the issuance of restricted stock units covering 40,700 shares of its common stock to thirty-one newly-hired employees. The grants were deemed necessary as inducement...